Likewise, the current advancement of therapeutic cancer vaccines can target prior steps of tumor antigen processing and presentation, and can also increase the potency of efficient CD8+ T cells against cancer, so neoantigen-based vaccines will especially become a vital addition to facilitate immune evasion in complex heterogeneous tumor microenvironments (TMEs)19. Here, CD8A is linked to cancer.